Kolon TissueGene, Inc.

Advanced Cell Therapies for Orthopedic Disorders

Kolon TissueGene is focused on developing advanced cell and gene therapies for musculoskeletal conditions with significant unmet medical needs.

Osteoarthritis
Knee
R&D PreClinical Phase I Phase II Phase III BLA
R&D Phase complete
PreClinical Phase complete
Phase I Phase complete
Phase II Phase complete
Phase III Phase in progress
BLA Phase not started
Hip
R&D PreClinical Phase I Phase II Phase III BLA
R&D Phase complete
PreClinical Phase complete
Phase I Phase in progress
Phase II Phase not started
Phase III Phase not started
BLA Phase not started
Musculoskeletal System Disorder
Spinal Disc
R&D PreClinical Phase I Phase II Phase III BLA
R&D Phase complete
PreClinical Phase in progress
Phase I Phase not started
Phase II Phase not started
Phase III Phase not started
BLA Phase not started
Veterinary Medicine
Knee1
R&D PreClinical Clinical Trial BLA
R&D Phase complete
PreClinical Phase in progress
Clinical Trial Phase not started
BLA Phase not started
  1. BLA, Biologics License Application.

What is Osteoarthritis?

Osteoarthritis (OA) is a chronic joint disorder characterized by progressive structural and functional degeneration of joint tissues, accompanied by pain, stiffness, swelling, and impaired mobility.

Currently, it is estimated that OA affects:

>33 Million adults in the US1
~528 Million adults worldwide2

With the increasing prevalence of OA, driven primarily by the increasing aging population and obesity epidemic, TG-C is being developed as a noninvasive treatment to address the symptoms.

1. Foster AL, et al. Distribution of arthritis subtypes among adults with arthritis in the United States, 2017–March 2020. Prev Chronic Dis 2025;22:E28.

2. Langworthy M, et al. Knee osteoarthritis: disease burden, available treatments, and emerging options. Ther Adv Musculoskelet Dis 2024;16:1759720X241273009.